End-Stage Renal Disease(ESRD)
Conditions
Interventions
Control Group:Standard dialysis therapy and complication management without study drug (placebo control)
Treatment Group:Oral compound glycyrrhizin tablets, three times daily, 3 tablets (75mg) each time, total daily dose 225mg, continuous use for 24 months
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Gender is not limited, age > 18 years; 2. Diagnosed with ESRD and receiving regular maintenance dialysis therapy (including hemodialysis or peritoneal dialysis) for =6 months; 3. Presence of pruritus caused by eczema or dermatitis; 4. No antibiotic use within 2 weeks prior to enrollment, and able to maintain a relatively regular diet; 5. No history of nephrotic syndrome or cholestasis (these patients may have abnormal 11ß-hydroxysteroid dehydrogenase activity).
Exclusion criteria
Exclusion criteria: 1. Confirmed history of stroke (cerebral infarction, cerebral hemorrhage) or other severe brain diseases (e.g., brain tumor, severe traumatic brain injury, epilepsy); 2. Diagnosed with central nervous system degenerative diseases such as dementia, Parkinson's disease, or multiple sclerosis; 3. Presence of severe mental or cognitive impairment making it impossible to cooperate with study-related assessments; 4. Recent use of probiotics; 5. Presence of gastrointestinal diseases that severely affect absorption or gut microbiota (e.g., inflammatory bowel disease, chronic diarrhea, short bowel syndrome); 6. Diagnosed with an uncured malignant tumor within the past 5 years; 7. Currently participating in other interventional clinical trials; 8. Refusal to sign the informed consent form or difficulty in cooperating with the study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to First Major Adverse Cardiovascular and Cerebrovascular Event (MACCE);Radiological Progression of Cerebral Small Vessel Disease (CSVD); | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma Trimethylamine N-oxide (TMAO) Concentration;Gut Microbiota Composition and Abundance; | — |
Countries
China
Contacts
Public ContactXue Jun
Huashan Hospital, Fudan University
Outcome results
None listed